Prion Protein Ligands for Selective Detection and Removal
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting and removing prions from biological samples are inadequate, as existing ligands are not effective in binding to prions across various media and none have shown significant potential in removing pre-existing prions from infected hosts, posing a risk for the transmission of transmissible spongiform encephalopathies (TSEs) such as vCJD through blood transfusion and food contamination.
Innovation Solution
Development of specific peptides that bind selectively and specifically to prion proteins, including cellular, infectious, and recombinant forms, which can be immobilized on resins or membranes to detect or remove prions from biological samples, thereby distinguishing between infectious and non-infectious prion proteins and potentially inhibiting the polymerization of the infectious form.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional serologic tests are used to detect prions, then the test methodology is simple, but the tests cannot detect prions because no antibodies are produced in TSE infections
Solution Approach 1:
The patent uses peptide ligands as intermediary molecules that specifically bind to prion proteins. These ligands serve as mediators between the prion target and the detection system, enabling detection without relying on host-produced antibodies. The ligands are immobilized on solid supports to create affinity-based detection assays that can specifically capture and detect prion proteins in biological samples.
2Reliability
If chemical and physical methods are used to inactivate prions, then the inactivation process is straightforward, but prions are remarkably resistant and selective inactivation is elusive
Solution Approach 1:
The patent extracts the prion protein from its resistant biological matrix by using specific peptide ligands that bind to unique structural features of prions. By immobilizing these ligands on solid supports, the method selectively extracts prions from complex biological samples through affinity binding, separating them from other proteins and materials that confer resistance to conventional inactivation methods.
Solution Approach 2:
The patent changes the binding parameters by using specifically designed peptide sequences that recognize and bind to conformational epitopes on prion proteins. This parameter change in molecular recognition enables selective capture of prions under mild conditions that preserve their structural integrity, allowing subsequent effective inactivation that would not be achievable with conventional methods alone.
3Adaptability or versatility
If broad-spectrum ligands are used to bind prions, then the ligands can bind to various prion forms, but they cannot distinguish between infectious and non-infectious prion proteins
Solution Approach 1:
The patent applies local quality by designing ligands with specific sequence characteristics that recognize particular local structural features of infectious prion proteins. The ligand sequences are optimized to bind to conformational epitopes that are exposed or uniquely structured in the infectious PrPSc form, rather than the native PrPC form, enabling selective detection and removal of the pathogenic variant.
4Reliability
If post-mortem histological examination is used to diagnose TSEs, then the diagnosis can be confirmed, but it requires death of the host and cannot prevent transmission
Solution Approach 1:
The patent enables preliminary action by providing methods to detect and remove prions from biological samples before transmission can occur. The affinity-based detection and removal methods can be applied to blood products, foodstuffs, and other materials during processing and preparation, identifying and eliminating infectious prions prior to their potential transmission to humans or animals.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptides effectively bind to prions across different species, enabling the detection and removal of prions from various samples, including blood and food products, thereby reducing the risk of TSE transmission and providing a therapeutic approach to retard the development of prion-associated pathologies.
Implementation Method 1
specific peptides that bind selectively and specifically to prion proteins
Implementation Method 2
ligands are immobilized on resins or membranes to detect or remove prions from biological samples
Data Source
AI summary
Ligands that bind to prion proteins and methods for using the ligands for detecting or removing a prion protein from a sample, such as a biological fluid or an environmental sample. The ligands are capable of binding to one or more forms of prion protein including cellular prion protein (PrPc), infectious prion protein (PrPsc), and recombinant prion protein (PrPr). Prions from various species, including humans and hamsters, are bound by the ligands. Also provided is a method of treating or retarding the development of a prion-associated pathology in a subject.